BDCA2 BLOOD DENDRITIC CELL ANTIGEN II ANTIBODIES LITIFILIMAB IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS-SLE

• DOI: 10.22533/at.ed.15935232001614

• Palavras-chave: Systemic lupus erythematosus, litifilimab and monoclonal antibodies.

• Keywords: Systemic lupus erythematosus, litifilimab and monoclonal antibodies.

• Abstract:

  Objective to evaluate the favorable and unfavorable results in the use of the antigen II antibody of blood dendritic cells BDCA 2, LITIFILIMAB in the treatment of systemic lupus erythematosus-SLE. Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) Systemic lupus erythematosus (ii) Litifilimab, (iii) Monoclonal antibodies, with the Boolean operator “AND”. Studies published from 2018 to 2022 were included. Results: Currently, there are several therapies for the treatment and control of systemic lupus erythematosus, as well as the test carried out for the anti-B antibody DCA2 or Litifilimab, which is the binding of antigen II of blood dendritic cells that is expressed only in plasmacytoid dendritic cells, where suppresses the production of interferon I, which is largely involved in the pathogenesis of systemic lupus erythematosus, Litifilimab was associated with a greater reduction in the number of affected joints, having this as a therapeutic advantage, but further studies are needed to verify safety and efficacy of the drug.